Clinical Trials › NCT05999604
RecruitingPhase 3
Impact of Annual Versus Biannual Infusions of Ocrelizumab in Patients With Active MS,After 2 Years of Initial Treatment, on Freedom From Radiological Disease Activity at Two Years: a Multicenter Randomized Controlled Non-inferiority Trial
Sponsored by Fondation Ophtalmologique Adolphe de Rothschild
Interested in joining? Eligibility criteria and contact info are on ClinicalTrials.gov.
View on ClinicalTrials.gov 244
Target enrollment
Nov 2023
Start date
Nov 2029
Expected completion
Interventions / Treatments
Ocrelizumab Injection [Ocrevus]
Conditions studied
Multiple Sclerosis
Trial locations
U.S. site locations haven't been posted yet for this trial. Check ClinicalTrials.gov for the latest contact and location info.
More Phase 3 trials
Browse all Phase 3 MS trialsThe app
Check out the MS Buddy app
Track symptoms, monitor wellness, and stay on top of your MS care. It’s free, with no ads. Built by people living with MS.